Body Mass Index and Diffuse Large B Cell Lymphoma (CROSBI ID 562267)
Prilog sa skupa u zborniku | sažetak izlaganja sa skupa
Podaci o odgovornosti
Marijić, Blažen ; Pećanić, Sanja ; Licul, Vanja ; Štifter, Sanja ; Jonjić, Nives ; Valković, Toni ; Petranović, Duška ; Načinović Duletić, Antica
engleski
Body Mass Index and Diffuse Large B Cell Lymphoma
Background: Biological plausibility and evidence from case series indicate that an increased body mass index (BMI) could be a risk factor for non Hodgkin lymphoma. In a population-based case-control study, obesity was associated with elevated odds ratios (ORs) for non-Hodgkin lymphoma (NHL), and the two major subtypes, diffuse large cell (DLCL) and follicular lymphoma (FL). There was need to find if BMI is correlating with response to therapy. The aim of this study was to analyze the association between body mass index, response to therapy in patient with DLBC. Also, we wanted investigate possible clinical usefulness of body mass index as prognostic parameter for treatment response in patients with this disease. Methods: This analysis included 94 patients with DLBCL, 46 men and 48 women with middle age of 66 years (18-87). Patients had clinical stage (CS) from I to IV according to Ann Arbor classification. We calculated BMI in the start of therapy and middle value was 26, 46 kg/m2 (18-35, 2). Patient received standard protocol for aggressive lymphomas (CHOP-R/CHOP protocol). On evaluation of disease, 43 patients were in complete remission (CR), 24 patients were in partial remission, and 29 were with progression of the disease. Also, in our study we included international prognostic index (IPI) with values from 0 to 5, Eastern Oncology Cooperative Group (EOCG) performance status with values from 0 to 4 and “B symptoms of disease (fever, night sweats, and weight loss). All those parameters were statistically compared with BMI. Results: No significant association was reported between BMI and response to therapy (p=0, 543), BMI and IPI (p= 0, 712), BMI and EOCG (p= 0, 835), BMI and CS (p=0, 996), BMI and B symptoms of disease (p=0, 356). Conclussion: According to this analysis it appears that BMI could not provide useful prognostic information and predict effects of therapy, but those are preeliminar results and we hope that in future investigations we will establish our theory.
BMI; DLBCL
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o prilogu
524-524.
2009.
nije evidentirano
objavljeno
Podaci o matičnoj publikaciji
BIT"s Life Science 2nd Annual World Cancer Congress, Beijing 2009, Abstract book
Peking:
Podaci o skupu
BITs Life Science 2nd Annual World Cancer Congress, Beijing 2009
poster
22.06.2009-25.06.2009
Peking, Kina